News & Updates

The use of denosumab demonstrates superior protection against bone mineral density (BMD) loss at 12 months compared with alendronate in older patients with newly diagnosed lymphoma receiving R-CHOP* and related regimens, as shown in the DENOSULY study.

A multi-pronged approach can help improve colorectal cancer (CRC) screening uptake in Singapore, suggests a recent study.

ARACOG, a phase II randomized trial, reports a significantly greater decline in objectively assessed cognitive function for advanced prostate cancer patients treated with enzalutamide vs darolutamide over 24 weeks, according to data presented at ASCO 2026.

Chiauranib plus weekly paclitaxel significantly extends progression-free survival (PFS) in patients with platinum-resistant or -refractory ovarian cancer, including those previously treated with anti-angiogenic agents, according to the findings of the phase III CHIPRO trial presented at ASCO 2026.

A recent study in UK has shown a significant proportion of patients with hepatitis C virus (HCV)-related hepatocellular carcinoma (HCC) initiating direct-acting antiviral (DAA) therapy, resulting in improvements in sustained virological response (SVR) rates.